Vienna-based nyra health, a supplier of an AI-based platform for neurological remedy, declares the completion of a €20 million Sequence A financing spherical to additional develop its know-how platform within the DACH area, speed up its growth within the US, and pursue its purpose of creating a brand new customary for data-driven neurorehabilitation.
The spherical is led by Armira Development. Current buyers akin to Wellington Companions, Crane Enterprise Companions, which now oversees MassMutual Ventures’ investments, and EVER Pharma are collaborating once more. This follows a €4.5 million Seed increase again in 2023, as covered by EU-Startups.
Moritz Schöllauf, CEO and co-founder, nyra well being, says: “From the outset, our purpose was to make our companies broadly out there to these affected. Everybody who wants remedy after a stroke or different neurological illness ought to have entry to efficient, individualised care – no matter the place they dwell or how effectively their very own healthcare system is about up. With this spherical of financing, we’re taking one other step on this route.”
Within the broader 2025–2026 funding panorama, a number of European health- and neurology-related ventures have additionally secured capital, illustrating sustained investor curiosity in neurological illness innovation and digital care instruments.
Notably, Aerska in Dublin raised round €17 million Seed to advance RNA interference-based medicines focusing on ailments of the central nervous system, geared toward addressing hard-to-treat mind problems. EG 427, a Paris-based BioTech, accomplished a €27 million Sequence B to propel genetic drugs programmes targeted on continual neurological circumstances.
Early-stage firms akin to Strolll, with a reported €12.2 million increase for augmented actuality functions in neurorehabilitation, and Neu Health (~€1.9 million) focusing on AI-enabled look after Parkinson’s and dementia, additional mirror exercise on the intersection of tech and neurological care.
In the meantime, Hemi Health in Denmark secured €4 million Seed financing to scale digital therapeutic and medical companies for migraine, concussion and headache problems.
Inside this context, nyra well being’s €20 million Sequence A for its AI-based neurorehabilitation platform aligns with a broader development of funding into neurological and HealthTech innovation throughout Europe.
Collectively these rounds add as much as over €60 million in funding, pointing to a various however converging concentrate on neurological illness biology, digital therapeutics and AI-driven care options, with buyers backing each drug-centric BioTech and software-enabled medical instruments within the sector.
Christian Figge, Managing Accomplice, Armira Development, provides: “Neurological rehabilitation might be made considerably more practical by means of digital options, particularly within the space of speech capacity. nyra well being is taken into account a real class creator with a proprietary AI-based answer that seamlessly connects your complete care chain – from inpatient remedy to outpatient aftercare to residence use – for the primary time.”
Based in 2021 by an interdisciplinary crew of consultants within the fields of neurology, machine studying, and regulatory affairs, nyra well being is growing an AI platform for neurological rehabilitation.
It’s presently utilized in over 100 rehabilitation clinics, within the digital rehabilitation aftercare programme of the German Pension Insurance coverage Fund, and by sufferers with the help of over 28 medical health insurance firms.
In line with the corporate, neurological ailments akin to stroke, dementia, and traumatic mind damage trigger €65 billion in prices yearly in Germany alone – primarily as a result of care typically stops or considerably decreases in depth after discharge from the hospital. This leads to gaps in look after these affected and rising prices as a result of insufficient follow-up care and avoidable long-term penalties for medical health insurance firms and value bearers.
myReha has reportedly been proven to considerably enhance remedy time whereas delivering substantial price financial savings: 28 statutory and personal medical health insurance firms already routinely reimburse myReha. Greater than 40 million insured people now have entry to structured, AI-based residence remedy with real-time suggestions.
“We had been additionally significantly impressed by the robust medical proof and deep integration into the German customary of care, which already offers nyra well being entry to over 40 million insured people. On this foundation, the corporate is ideally positioned to outline the marketplace for digital neurorehabilitation internationally as effectively,” shares Christian.
At its coronary heart is the MDR Class IIa licensed medical gadget myReha. Sufferers practice speech, cognition, tremendous motor abilities, and on a regular basis skills with AI-supported real-time suggestions. Specifically developed speech fashions analyse pathological speech on the degree of pronunciation, phrase retrieval, syntax, and semantic construction. On the similar time, response occasions, error profiles, and coaching dynamics are repeatedly evaluated.
Based mostly on this information, the remedy routinely adapts to efficiency degree, fatigue, and progress. In a randomized managed examine, the extra use of myReha confirmed considerably larger enhancements in cognitive and language capabilities in comparison with customary remedy.
On the similar time, nyra insights constructions the management by specialists: therapists see language developments, remedy depth, and progress curves in actual time, modify packages, and create documentation routinely. That is complemented by the AI-supported Content material Studio, which dynamically generates personalised remedy content material particularly for remedy practices primarily based on particular person efficiency information.
After in the present day’s announcement, further clinic teams within the DACH area shall be related and current reimbursement fashions in Germany, Austria, and Switzerland shall be expanded in a focused method. On the similar time, the corporate is making ready to enter the US market.
nyra well being can be investing within the technological development of its platform. The main focus is on increasing multimodal AI fashions for therapeutic interplay and diagnostics. These are being developed as a part of a funded analysis mission value €4.2 million and scientifically validated in collaboration with main US analysis universities.
